Source link : https://www.newshealth.biz/health-news/interim-align-data-atrasentan-cuts-proteinuria-in-iga-nephropathy/
SAN DIEGO — A novel drug significantly reduced IgA nephropathy-related proteinuria, according to interim findings of the ALIGN study. In the phase III trial, among 270 patients with the rare kidney disorder, those on atrasentan had a 36.1 percentage point (95% CI -44.6 to -26.4, PAmerican Society of Nephrology Kidney Week meeting. Over the course […]
Author : News Health
Publish date : 2024-10-27 21:28:31
Copyright for syndicated content belongs to the linked Source.
